Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.65 USD | +2.48% | +4.34% | +157.80% |
Apr. 11 | North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge | DJ |
Apr. 10 | Vera Therapeutics Shares Rise 9.9% After Alpine Acquisition | DJ |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 568.5 | 535.2 | 683.4 | 2,159 | - | - |
Enterprise Value (EV) 1 | 568.5 | 535.2 | 683.4 | 2,452 | 2,159 | 2,159 |
P/E ratio | -11 x | -5.78 x | -6.84 x | -18.3 x | -16.9 x | -15.8 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | 54.8 x |
EV / Revenue | - | - | - | - | - | 54.8 x |
EV / EBITDA | - | -5.94 x | -6.98 x | -20.4 x | -14.9 x | - |
EV / FCF | -24 x | -7.91 x | -7.41 x | -23.1 x | -17.8 x | -18.4 x |
FCF Yield | -4.17% | -12.6% | -13.5% | -4.32% | -5.6% | -5.42% |
Price to Book | - | 6.99 x | 6.72 x | 7.19 x | 8.44 x | - |
Nbr of stocks (in thousands) | 21,278 | 27,658 | 44,433 | 54,452 | - | - |
Reference price 2 | 26.72 | 19.35 | 15.38 | 39.65 | 39.65 | 39.65 |
Announcement Date | 3/28/22 | 3/28/23 | 3/20/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | 39.37 |
EBITDA 1 | - | - | -90.06 | -97.93 | -120 | -145 | - |
EBIT 1 | - | -34.4 | -90.9 | -102 | -119 | -134.1 | -131.8 |
Operating Margin | - | - | - | - | - | - | -334.84% |
Earnings before Tax (EBT) 1 | - | -32.61 | -89.06 | -95.99 | -117.6 | -132.5 | -150.8 |
Net income 1 | -53.41 | -32.61 | -89.06 | -95.99 | -117.7 | -130.4 | -148.6 |
Net margin | - | - | - | - | - | - | -377.34% |
EPS 2 | -14.40 | -2.430 | -3.350 | -2.250 | -2.162 | -2.343 | -2.513 |
Free Cash Flow 1 | - | -23.71 | -67.66 | -92.24 | -105.9 | -121 | -117.1 |
FCF margin | - | - | - | - | - | - | -297.39% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 3/19/21 | 3/28/22 | 3/28/23 | 3/20/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA 1 | - | - | - | -15.16 | -25.4 | -32.98 | -31.76 | -22.94 | - | -25.86 | -28 | -29 | -31 | -32 | - |
EBIT 1 | -7.252 | -16.58 | -17.02 | -15.06 | -25.24 | -33.58 | -31.26 | -21.97 | -21.76 | -27.03 | -28 | -29.5 | -30.72 | -32.11 | -35.17 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -7.611 | -16.85 | -17.08 | -14.85 | -24.68 | -32.44 | -30.07 | -20.16 | -20.1 | -25.65 | -27.87 | -28.82 | -30.1 | -31.55 | -32.94 |
Net income 1 | -7.611 | -16.85 | -17.08 | -14.85 | -24.68 | -32.44 | -30.07 | -20.16 | -20.1 | -25.66 | -27.87 | -28.82 | -30.1 | -31.55 | -32.94 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.3600 | -0.9700 | -0.7100 | -0.5500 | -0.9100 | -1.190 | -0.8000 | -0.4600 | -0.4500 | -0.5800 | -0.5296 | -0.5331 | -0.5501 | -0.5647 | -0.6000 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 11/10/21 | 3/28/22 | 5/16/22 | 8/10/22 | 11/9/22 | 3/28/23 | 5/11/23 | 8/10/23 | 11/9/23 | 3/20/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | 293 | - | - |
Net Cash position 1 | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | -2.444 x | - | - |
Free Cash Flow 1 | - | -23.7 | -67.7 | -92.2 | -106 | -121 | -117 |
ROE (net income / shareholders' equity) | - | - | -122% | -107% | -52.6% | -49.2% | - |
ROA (Net income/ Total Assets) | - | - | -82.8% | -62.5% | -48.5% | -46.5% | - |
Assets 1 | - | - | 107.6 | 153.5 | 242.4 | 280.3 | - |
Book Value Per Share 2 | - | - | 2.770 | 2.290 | 5.520 | 4.700 | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex 1 | - | - | - | 0.06 | 0.1 | 0.12 | 0.12 |
Capex / Sales | - | - | - | - | - | - | 0.31% |
Announcement Date | 3/19/21 | 3/28/22 | 3/28/23 | 3/20/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+157.80% | 2.16B | |
+1.51% | 42.75B | |
+48.26% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- VERA Stock
- Financials Vera Therapeutics, Inc.